Compare NCNO & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCNO | IDYA |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.9B |
| IPO Year | 2022 | 2019 |
| Metric | NCNO | IDYA |
|---|---|---|
| Price | $18.09 | $32.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 16 |
| Target Price | $26.07 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 3.3M | 1.4M |
| Earning Date | 05-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.15 | 61.90 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $594,781,000.00 | $218,710,000.00 |
| Revenue This Year | $10.01 | N/A |
| Revenue Next Year | $8.90 | $199.11 |
| P/E Ratio | $349.40 | ★ N/A |
| Revenue Growth | 10.01 | ★ 3024.43 |
| 52 Week Low | $13.80 | $16.07 |
| 52 Week High | $33.92 | $39.28 |
| Indicator | NCNO | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 61.19 | 48.87 |
| Support Level | $13.80 | $29.29 |
| Resistance Level | $18.45 | $34.76 |
| Average True Range (ATR) | 0.92 | 2.15 |
| MACD | 0.30 | 0.06 |
| Stochastic Oscillator | 90.43 | 23.95 |
Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.